Table 6.6UIncreased risk/benefit for high/low Hb in NON-DIALYSIS patients

Comparison: >12 g/dL versus lower Hb; [The aspirational Hb levels are noted within the square brackets]

High Hb target g/dLLow Hb target
Increased risk in the higher Hb group for:Composite events*
[13–15 vs >9–11.5]
Stroke
[13–15 vs >9–11.5]
Hypertension
[12–15 vs 9–12]
Initiation of dialysis
[12–15 vs 9–11.5]
Worse CV event free survival (in patients with eccentric LVH at baseline)
[13–15 vs 10.5–12.5]
No difference
  • Mortality
  • CV mortality
  • Progression of CKD [mean decrease in GFR; creatinine clearance]
  • Change in LVMI
  • QoL (physical function, physical role, pain, role –emotional, social function, mental health, physical health composite score and mental health composite score)
Increased benefit in the higher Hb group for:Lower transfusion requirements
[13–15 vs >9–11.5]
QoL:
  • General health
    [13–15 v 10.5–12]
  • Vitality
    [13–15 vs >9–12]
*

Composite events included: time to a first CV event, death from any cause or CV event and time to death, MI, hospitalisation for CHF and stroke

borderline significant

Composite events included: time to a first CV event, death from any cause or CV event and time to death, MI, hospitalisation for CHF and stroke

borderline significant

From: 6, Assessment and optimisation of erythropoiesis

Cover of Anaemia Management in Chronic Kidney Disease
Anaemia Management in Chronic Kidney Disease: Rapid Update 2011 [Internet].
NICE Clinical Guidelines, No. 114.
National Clinical Guideline Centre (UK).
Copyright © 2011, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.